nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Bexarotene—hematologic cancer	0.0363	0.0829	CbGbCtD
Maraviroc—CYP3A4—Lomustine—hematologic cancer	0.0337	0.0771	CbGbCtD
Maraviroc—CYP3A4—Busulfan—hematologic cancer	0.0337	0.0771	CbGbCtD
Maraviroc—CYP3A4—Thiotepa—hematologic cancer	0.0301	0.0687	CbGbCtD
Maraviroc—CYP3A4—Methoxsalen—hematologic cancer	0.0234	0.0534	CbGbCtD
Maraviroc—CYP3A4—Bortezomib—hematologic cancer	0.0222	0.0508	CbGbCtD
Maraviroc—CYP3A4—Daunorubicin—hematologic cancer	0.0213	0.0486	CbGbCtD
Maraviroc—CYP3A4—Cytarabine—hematologic cancer	0.0188	0.0429	CbGbCtD
Maraviroc—CYP3A4—Teniposide—hematologic cancer	0.0185	0.0422	CbGbCtD
Maraviroc—CYP3A4—Ifosfamide—hematologic cancer	0.0171	0.039	CbGbCtD
Maraviroc—CYP3A4—Imatinib—hematologic cancer	0.0163	0.0372	CbGbCtD
Maraviroc—CYP3A4—Ruxolitinib—hematologic cancer	0.0153	0.0351	CbGbCtD
Maraviroc—CYP3A4—Nilotinib—hematologic cancer	0.0148	0.0338	CbGbCtD
Maraviroc—CYP3A4—Vinorelbine—hematologic cancer	0.0147	0.0335	CbGbCtD
Maraviroc—CCR5—hematopoietic system—hematologic cancer	0.0145	0.356	CbGeAlD
Maraviroc—CYP3A4—Triamcinolone—hematologic cancer	0.0134	0.0307	CbGbCtD
Maraviroc—CYP3A4—Dasatinib—hematologic cancer	0.0131	0.0299	CbGbCtD
Maraviroc—CYP3A4—Mitoxantrone—hematologic cancer	0.0129	0.0295	CbGbCtD
Maraviroc—CYP3A4—Betamethasone—hematologic cancer	0.0115	0.0263	CbGbCtD
Maraviroc—CYP3A4—Prednisolone—hematologic cancer	0.0114	0.026	CbGbCtD
Maraviroc—CYP3A4—Prednisone—hematologic cancer	0.0107	0.0245	CbGbCtD
Maraviroc—CYP3A4—Irinotecan—hematologic cancer	0.0102	0.0233	CbGbCtD
Maraviroc—CCR5—blood—hematologic cancer	0.00962	0.236	CbGeAlD
Maraviroc—CYP3A4—Vinblastine—hematologic cancer	0.00905	0.0207	CbGbCtD
Maraviroc—CYP3A4—Vincristine—hematologic cancer	0.00889	0.0203	CbGbCtD
Maraviroc—CCR5—lung—hematologic cancer	0.00843	0.207	CbGeAlD
Maraviroc—CYP3A4—Etoposide—hematologic cancer	0.00815	0.0186	CbGbCtD
Maraviroc—CYP3A4—Dexamethasone—hematologic cancer	0.0067	0.0153	CbGbCtD
Maraviroc—CCR5—lymph node—hematologic cancer	0.00577	0.141	CbGeAlD
Maraviroc—CYP3A4—Doxorubicin—hematologic cancer	0.00556	0.0127	CbGbCtD
Maraviroc—CYP3A4—hematopoietic system—hematologic cancer	0.00146	0.0359	CbGeAlD
Maraviroc—CYP3A4—blood—hematologic cancer	0.00097	0.0238	CbGeAlD
Maraviroc—CCR5—Signaling Pathways—DKK1—hematologic cancer	9.05e-05	0.000557	CbGpPWpGaD
Maraviroc—CCR5—Disease—HSP90AA1—hematologic cancer	9e-05	0.000554	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT5B—hematologic cancer	8.98e-05	0.000552	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ADCY7—hematologic cancer	8.72e-05	0.000536	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT1—hematologic cancer	8.68e-05	0.000534	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CSF2—hematologic cancer	8.6e-05	0.000529	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2RA—hematologic cancer	8.53e-05	0.000525	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—XIAP—hematologic cancer	8.48e-05	0.000522	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	8.41e-05	0.000518	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—JAK1—hematologic cancer	8.3e-05	0.000511	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PRKCG—hematologic cancer	8.3e-05	0.000511	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	8.3e-05	0.000511	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SMARCA4—hematologic cancer	8.26e-05	0.000508	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SH2B3—hematologic cancer	8.26e-05	0.000508	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GZMB—hematologic cancer	8.21e-05	0.000505	CbGpPWpGaD
Maraviroc—CCR5—Disease—GRB2—hematologic cancer	8.12e-05	0.000499	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFA—hematologic cancer	8.1e-05	0.000498	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNA1—hematologic cancer	8.02e-05	0.000493	CbGpPWpGaD
Maraviroc—CCR5—Disease—KITLG—hematologic cancer	7.98e-05	0.000491	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EIF4EBP1—hematologic cancer	7.97e-05	0.00049	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HSPB1—hematologic cancer	7.97e-05	0.00049	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL3—hematologic cancer	7.97e-05	0.00049	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTHLH—hematologic cancer	7.88e-05	0.000485	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SDC1—hematologic cancer	7.88e-05	0.000485	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT5A—hematologic cancer	7.8e-05	0.00048	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2RA—hematologic cancer	7.75e-05	0.000477	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN2B—hematologic cancer	7.73e-05	0.000476	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTGER4—hematologic cancer	7.67e-05	0.000472	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—LCK—hematologic cancer	7.63e-05	0.00047	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—H3F3A—hematologic cancer	7.48e-05	0.00046	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD86—hematologic cancer	7.48e-05	0.00046	CbGpPWpGaD
Maraviroc—CCR5—Disease—HES1—hematologic cancer	7.38e-05	0.000454	CbGpPWpGaD
Maraviroc—CCR5—Disease—NCOR1—hematologic cancer	7.34e-05	0.000451	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRKCZ—hematologic cancer	7.27e-05	0.000448	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGF1—hematologic cancer	7.25e-05	0.000446	CbGpPWpGaD
Maraviroc—CCR5—Disease—FOXO1—hematologic cancer	7.15e-05	0.00044	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFRB—hematologic cancer	7.14e-05	0.000439	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—hematologic cancer	7.11e-05	0.000437	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PARP1—hematologic cancer	7.03e-05	0.000432	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFRA—hematologic cancer	7.02e-05	0.000432	CbGpPWpGaD
Maraviroc—CCR5—Disease—PRKCG—hematologic cancer	7e-05	0.000431	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAK1—hematologic cancer	7e-05	0.000431	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FBXW7—hematologic cancer	6.91e-05	0.000425	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCR4—hematologic cancer	6.78e-05	0.000417	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HDAC2—hematologic cancer	6.78e-05	0.000417	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CBL—hematologic cancer	6.61e-05	0.000406	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL3—hematologic cancer	6.54e-05	0.000402	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTHFR—hematologic cancer	6.48e-05	0.000399	CbGpPWpGaD
Maraviroc—CCR5—Disease—TERT—hematologic cancer	6.46e-05	0.000398	CbGpPWpGaD
Maraviroc—CCR5—Disease—HLA-A—hematologic cancer	6.46e-05	0.000398	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—hematologic cancer	6.46e-05	0.000397	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTPN1—hematologic cancer	6.43e-05	0.000395	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PTPN11—hematologic cancer	6.34e-05	0.00039	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RASGRP1—hematologic cancer	6.32e-05	0.000389	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFB—hematologic cancer	6.31e-05	0.000388	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HSP90AA1—hematologic cancer	6.3e-05	0.000388	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SYK—hematologic cancer	6.3e-05	0.000388	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CD—hematologic cancer	6.25e-05	0.000385	CbGpPWpGaD
Maraviroc—CCR5—Disease—TSC2—hematologic cancer	6.17e-05	0.000379	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CREB1—hematologic cancer	6.15e-05	0.000378	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT1—hematologic cancer	6.08e-05	0.000374	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CCL2—hematologic cancer	6.01e-05	0.00037	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6R—hematologic cancer	6e-05	0.000369	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGFR3—hematologic cancer	5.93e-05	0.000365	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3R1—hematologic cancer	5.9e-05	0.000363	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—JAK2—hematologic cancer	5.74e-05	0.000353	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAP2K1—hematologic cancer	5.71e-05	0.000352	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GRB2—hematologic cancer	5.68e-05	0.00035	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—hematologic cancer	5.68e-05	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFA—hematologic cancer	5.67e-05	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Disease—BAD—hematologic cancer	5.62e-05	0.000346	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KITLG—hematologic cancer	5.59e-05	0.000344	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOTCH1—hematologic cancer	5.57e-05	0.000343	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT5A—hematologic cancer	5.46e-05	0.000336	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD80—hematologic cancer	5.46e-05	0.000336	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—hematologic cancer	5.45e-05	0.000335	CbGpPWpGaD
Maraviroc—CCR5—Disease—KIT—hematologic cancer	5.45e-05	0.000335	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	5.42e-05	0.000334	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN2B—hematologic cancer	5.42e-05	0.000333	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3R1—hematologic cancer	5.36e-05	0.00033	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTPN11—hematologic cancer	5.35e-05	0.000329	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	5.35e-05	0.000329	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CD86—hematologic cancer	5.24e-05	0.000322	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—JAK2—hematologic cancer	5.21e-05	0.000321	CbGpPWpGaD
Maraviroc—CCR5—Disease—CREB1—hematologic cancer	5.18e-05	0.000319	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HES1—hematologic cancer	5.17e-05	0.000318	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NCOR1—hematologic cancer	5.14e-05	0.000316	CbGpPWpGaD
Maraviroc—CCR5—Disease—BRAF—hematologic cancer	5.12e-05	0.000315	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	5.1e-05	0.000314	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF1—hematologic cancer	5.08e-05	0.000313	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CSF2—hematologic cancer	5.08e-05	0.000313	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6R—hematologic cancer	5.06e-05	0.000311	CbGpPWpGaD
Maraviroc—CCR5—Disease—CREBBP—hematologic cancer	5.05e-05	0.000311	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	5.03e-05	0.000309	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FOXO1—hematologic cancer	5.01e-05	0.000308	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—hematologic cancer	5e-05	0.000308	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFRB—hematologic cancer	5e-05	0.000307	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—hematologic cancer	4.95e-05	0.000304	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFRA—hematologic cancer	4.92e-05	0.000303	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JAK1—hematologic cancer	4.9e-05	0.000302	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRKCG—hematologic cancer	4.9e-05	0.000302	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAP2K1—hematologic cancer	4.82e-05	0.000297	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CD—hematologic cancer	4.79e-05	0.000295	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGF2—hematologic cancer	4.58e-05	0.000282	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2RA—hematologic cancer	4.58e-05	0.000282	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—hematologic cancer	4.54e-05	0.00028	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TERT—hematologic cancer	4.53e-05	0.000279	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3R1—hematologic cancer	4.52e-05	0.000278	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	4.5e-05	0.000277	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—MTR—hematologic cancer	4.42e-05	0.000272	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFB—hematologic cancer	4.42e-05	0.000272	CbGpPWpGaD
Maraviroc—CCR5—Disease—JAK2—hematologic cancer	4.39e-05	0.00027	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TSC2—hematologic cancer	4.32e-05	0.000266	CbGpPWpGaD
Maraviroc—CCR5—Disease—MDM2—hematologic cancer	4.29e-05	0.000264	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	4.2e-05	0.000259	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CB—hematologic cancer	4.17e-05	0.000257	CbGpPWpGaD
Maraviroc—CCR5—Disease—MTOR—hematologic cancer	4.17e-05	0.000257	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD4—hematologic cancer	4.17e-05	0.000256	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGFR3—hematologic cancer	4.15e-05	0.000256	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK14—hematologic cancer	4.11e-05	0.000253	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ESR1—hematologic cancer	4.04e-05	0.000248	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FN1—hematologic cancer	3.99e-05	0.000245	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NFKBIA—hematologic cancer	3.94e-05	0.000242	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BAD—hematologic cancer	3.94e-05	0.000242	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1B—hematologic cancer	3.92e-05	0.000241	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—hematologic cancer	3.9e-05	0.00024	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CD80—hematologic cancer	3.82e-05	0.000235	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—hematologic cancer	3.81e-05	0.000235	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KIT—hematologic cancer	3.81e-05	0.000235	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—NRAS—hematologic cancer	3.81e-05	0.000235	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTPN11—hematologic cancer	3.75e-05	0.000231	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—hematologic cancer	3.65e-05	0.000225	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CREB1—hematologic cancer	3.63e-05	0.000223	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1A—hematologic cancer	3.61e-05	0.000222	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—hematologic cancer	3.61e-05	0.000222	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BRAF—hematologic cancer	3.59e-05	0.000221	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCL2—hematologic cancer	3.55e-05	0.000219	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6R—hematologic cancer	3.54e-05	0.000218	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CREBBP—hematologic cancer	3.54e-05	0.000218	CbGpPWpGaD
Maraviroc—CCR5—Disease—EP300—hematologic cancer	3.44e-05	0.000212	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAP2K1—hematologic cancer	3.38e-05	0.000208	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—hematologic cancer	3.35e-05	0.000206	CbGpPWpGaD
Maraviroc—CCR5—Disease—SRC—hematologic cancer	3.34e-05	0.000206	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—hematologic cancer	3.32e-05	0.000204	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—hematologic cancer	3.28e-05	0.000202	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—hematologic cancer	3.23e-05	0.000198	CbGpPWpGaD
Maraviroc—CCR5—Disease—NRAS—hematologic cancer	3.22e-05	0.000198	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF2—hematologic cancer	3.21e-05	0.000198	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3R1—hematologic cancer	3.17e-05	0.000195	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK3—hematologic cancer	3.08e-05	0.00019	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—JAK2—hematologic cancer	3.08e-05	0.000189	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—hematologic cancer	3.02e-05	0.000186	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MDM2—hematologic cancer	3e-05	0.000185	CbGpPWpGaD
Maraviroc—CCR5—Disease—MYC—hematologic cancer	3e-05	0.000184	CbGpPWpGaD
Maraviroc—CCR5—Disease—TGFB1—hematologic cancer	2.99e-05	0.000184	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—hematologic cancer	2.92e-05	0.00018	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MTOR—hematologic cancer	2.92e-05	0.00018	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	2.91e-05	0.000179	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	2.87e-05	0.000177	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—hematologic cancer	2.79e-05	0.000172	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—hematologic cancer	2.77e-05	0.00017	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1B—hematologic cancer	2.74e-05	0.000169	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—hematologic cancer	2.71e-05	0.000167	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—hematologic cancer	2.69e-05	0.000165	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—hematologic cancer	2.68e-05	0.000165	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	2.68e-05	0.000165	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—hematologic cancer	2.67e-05	0.000164	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	2.64e-05	0.000162	CbGpPWpGaD
Maraviroc—Convulsion—Prednisone—hematologic cancer	2.63e-05	7.32e-05	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—hematologic cancer	2.62e-05	7.31e-05	CcSEcCtD
Maraviroc—Agranulocytosis—Doxorubicin—hematologic cancer	2.62e-05	7.3e-05	CcSEcCtD
Maraviroc—Rash—Irinotecan—hematologic cancer	2.62e-05	7.29e-05	CcSEcCtD
Maraviroc—Rash—Mitoxantrone—hematologic cancer	2.62e-05	7.29e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CCND1—hematologic cancer	2.62e-05	0.000161	CbGpPWpGaD
Maraviroc—Dermatitis—Mitoxantrone—hematologic cancer	2.62e-05	7.29e-05	CcSEcCtD
Maraviroc—Dermatitis—Irinotecan—hematologic cancer	2.62e-05	7.29e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—JUN—hematologic cancer	2.61e-05	0.000161	CbGpPWpGaD
Maraviroc—Headache—Irinotecan—hematologic cancer	2.6e-05	7.25e-05	CcSEcCtD
Maraviroc—Headache—Mitoxantrone—hematologic cancer	2.6e-05	7.25e-05	CcSEcCtD
Maraviroc—Nausea—Ifosfamide—hematologic cancer	2.6e-05	7.24e-05	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Betamethasone—hematologic cancer	2.59e-05	7.21e-05	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	2.59e-05	7.21e-05	CcSEcCtD
Maraviroc—Myalgia—Prednisone—hematologic cancer	2.58e-05	7.19e-05	CcSEcCtD
Maraviroc—Diarrhoea—Cisplatin—hematologic cancer	2.58e-05	7.19e-05	CcSEcCtD
Maraviroc—Erythema multiforme—Epirubicin—hematologic cancer	2.58e-05	7.18e-05	CcSEcCtD
Maraviroc—Anxiety—Prednisone—hematologic cancer	2.57e-05	7.17e-05	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—hematologic cancer	2.57e-05	7.17e-05	CcSEcCtD
Maraviroc—Vomiting—Gemcitabine—hematologic cancer	2.57e-05	7.16e-05	CcSEcCtD
Maraviroc—Insomnia—Dexamethasone—hematologic cancer	2.57e-05	7.16e-05	CcSEcCtD
Maraviroc—Insomnia—Betamethasone—hematologic cancer	2.57e-05	7.16e-05	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	2.56e-05	7.14e-05	CcSEcCtD
Maraviroc—Paraesthesia—Betamethasone—hematologic cancer	2.55e-05	7.11e-05	CcSEcCtD
Maraviroc—Paraesthesia—Dexamethasone—hematologic cancer	2.55e-05	7.11e-05	CcSEcCtD
Maraviroc—Discomfort—Prednisone—hematologic cancer	2.55e-05	7.11e-05	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—hematologic cancer	2.55e-05	7.11e-05	CcSEcCtD
Maraviroc—Rash—Gemcitabine—hematologic cancer	2.55e-05	7.1e-05	CcSEcCtD
Maraviroc—Dermatitis—Gemcitabine—hematologic cancer	2.55e-05	7.1e-05	CcSEcCtD
Maraviroc—Eye disorder—Epirubicin—hematologic cancer	2.55e-05	7.09e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Etoposide—hematologic cancer	2.54e-05	7.09e-05	CcSEcCtD
Maraviroc—CCR5—Disease—PIK3CA—hematologic cancer	2.54e-05	0.000157	CbGpPWpGaD
Maraviroc—Erythema—Methotrexate—hematologic cancer	2.54e-05	7.06e-05	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—hematologic cancer	2.54e-05	7.06e-05	CcSEcCtD
Maraviroc—Headache—Gemcitabine—hematologic cancer	2.53e-05	7.06e-05	CcSEcCtD
Maraviroc—Nausea—Vincristine—hematologic cancer	2.53e-05	7.05e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—hematologic cancer	2.53e-05	0.000156	CbGpPWpGaD
Maraviroc—Cardiac disorder—Epirubicin—hematologic cancer	2.53e-05	7.05e-05	CcSEcCtD
Maraviroc—Rhinitis—Doxorubicin—hematologic cancer	2.53e-05	7.04e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PTEN—hematologic cancer	2.53e-05	0.000155	CbGpPWpGaD
Maraviroc—Hypersensitivity—Prednisolone—hematologic cancer	2.51e-05	6.99e-05	CcSEcCtD
Maraviroc—Pharyngitis—Doxorubicin—hematologic cancer	2.5e-05	6.97e-05	CcSEcCtD
Maraviroc—Urinary tract disorder—Doxorubicin—hematologic cancer	2.49e-05	6.94e-05	CcSEcCtD
Maraviroc—Asthenia—Etoposide—hematologic cancer	2.48e-05	6.9e-05	CcSEcCtD
Maraviroc—Connective tissue disorder—Doxorubicin—hematologic cancer	2.48e-05	6.9e-05	CcSEcCtD
Maraviroc—Body temperature increased—Triamcinolone—hematologic cancer	2.48e-05	6.9e-05	CcSEcCtD
Maraviroc—Oedema—Prednisone—hematologic cancer	2.48e-05	6.9e-05	CcSEcCtD
Maraviroc—Angiopathy—Epirubicin—hematologic cancer	2.47e-05	6.89e-05	CcSEcCtD
Maraviroc—Urethral disorder—Doxorubicin—hematologic cancer	2.47e-05	6.89e-05	CcSEcCtD
Maraviroc—Decreased appetite—Betamethasone—hematologic cancer	2.47e-05	6.88e-05	CcSEcCtD
Maraviroc—Decreased appetite—Dexamethasone—hematologic cancer	2.47e-05	6.88e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAPK8—hematologic cancer	2.47e-05	0.000152	CbGpPWpGaD
Maraviroc—Nausea—Mitoxantrone—hematologic cancer	2.47e-05	6.87e-05	CcSEcCtD
Maraviroc—Nausea—Irinotecan—hematologic cancer	2.47e-05	6.87e-05	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKT1—hematologic cancer	2.46e-05	0.000152	CbGpPWpGaD
Maraviroc—Infection—Prednisone—hematologic cancer	2.46e-05	6.85e-05	CcSEcCtD
Maraviroc—Mediastinal disorder—Epirubicin—hematologic cancer	2.46e-05	6.84e-05	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.45e-05	6.84e-05	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.45e-05	6.84e-05	CcSEcCtD
Maraviroc—Fatigue—Dexamethasone—hematologic cancer	2.45e-05	6.83e-05	CcSEcCtD
Maraviroc—Fatigue—Betamethasone—hematologic cancer	2.45e-05	6.83e-05	CcSEcCtD
Maraviroc—Pruritus—Etoposide—hematologic cancer	2.44e-05	6.81e-05	CcSEcCtD
Maraviroc—Shock—Prednisone—hematologic cancer	2.44e-05	6.78e-05	CcSEcCtD
Maraviroc—Pain—Dexamethasone—hematologic cancer	2.43e-05	6.77e-05	CcSEcCtD
Maraviroc—Pain—Betamethasone—hematologic cancer	2.43e-05	6.77e-05	CcSEcCtD
Maraviroc—Nervous system disorder—Prednisone—hematologic cancer	2.43e-05	6.76e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—EP300—hematologic cancer	2.41e-05	0.000148	CbGpPWpGaD
Maraviroc—Alopecia—Epirubicin—hematologic cancer	2.41e-05	6.71e-05	CcSEcCtD
Maraviroc—Skin disorder—Prednisone—hematologic cancer	2.4e-05	6.7e-05	CcSEcCtD
Maraviroc—Nausea—Gemcitabine—hematologic cancer	2.4e-05	6.69e-05	CcSEcCtD
Maraviroc—Vomiting—Cisplatin—hematologic cancer	2.4e-05	6.68e-05	CcSEcCtD
Maraviroc—Mental disorder—Epirubicin—hematologic cancer	2.39e-05	6.65e-05	CcSEcCtD
Maraviroc—Erythema multiforme—Doxorubicin—hematologic cancer	2.38e-05	6.64e-05	CcSEcCtD
Maraviroc—Rash—Cisplatin—hematologic cancer	2.38e-05	6.62e-05	CcSEcCtD
Maraviroc—Dermatitis—Cisplatin—hematologic cancer	2.38e-05	6.62e-05	CcSEcCtD
Maraviroc—Erythema—Epirubicin—hematologic cancer	2.37e-05	6.61e-05	CcSEcCtD
Maraviroc—Malnutrition—Epirubicin—hematologic cancer	2.37e-05	6.61e-05	CcSEcCtD
Maraviroc—Diarrhoea—Etoposide—hematologic cancer	2.36e-05	6.58e-05	CcSEcCtD
Maraviroc—Anorexia—Prednisone—hematologic cancer	2.36e-05	6.57e-05	CcSEcCtD
Maraviroc—Eye disorder—Doxorubicin—hematologic cancer	2.36e-05	6.56e-05	CcSEcCtD
Maraviroc—CCR5—Disease—HRAS—hematologic cancer	2.35e-05	0.000145	CbGpPWpGaD
Maraviroc—Anaemia—Methotrexate—hematologic cancer	2.34e-05	6.53e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SRC—hematologic cancer	2.34e-05	0.000144	CbGpPWpGaD
Maraviroc—Cardiac disorder—Doxorubicin—hematologic cancer	2.34e-05	6.52e-05	CcSEcCtD
Maraviroc—Flatulence—Epirubicin—hematologic cancer	2.34e-05	6.51e-05	CcSEcCtD
Maraviroc—Gastrointestinal pain—Betamethasone—hematologic cancer	2.32e-05	6.47e-05	CcSEcCtD
Maraviroc—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.32e-05	6.47e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Triamcinolone—hematologic cancer	2.31e-05	6.43e-05	CcSEcCtD
Maraviroc—Angiopathy—Doxorubicin—hematologic cancer	2.29e-05	6.37e-05	CcSEcCtD
Maraviroc—Dizziness—Etoposide—hematologic cancer	2.28e-05	6.36e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—VEGFA—hematologic cancer	2.28e-05	0.00014	CbGpPWpGaD
Maraviroc—Mediastinal disorder—Doxorubicin—hematologic cancer	2.27e-05	6.33e-05	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—hematologic cancer	2.27e-05	6.32e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—STAT3—hematologic cancer	2.26e-05	0.000139	CbGpPWpGaD
Maraviroc—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.26e-05	6.28e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—NRAS—hematologic cancer	2.25e-05	0.000139	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—hematologic cancer	2.25e-05	0.000139	CbGpPWpGaD
Maraviroc—Dizziness—Prednisolone—hematologic cancer	2.25e-05	6.28e-05	CcSEcCtD
Maraviroc—Asthenia—Triamcinolone—hematologic cancer	2.25e-05	6.26e-05	CcSEcCtD
Maraviroc—Body temperature increased—Betamethasone—hematologic cancer	2.25e-05	6.26e-05	CcSEcCtD
Maraviroc—Abdominal pain—Dexamethasone—hematologic cancer	2.25e-05	6.26e-05	CcSEcCtD
Maraviroc—Body temperature increased—Dexamethasone—hematologic cancer	2.25e-05	6.26e-05	CcSEcCtD
Maraviroc—Abdominal pain—Betamethasone—hematologic cancer	2.25e-05	6.26e-05	CcSEcCtD
Maraviroc—Nausea—Cisplatin—hematologic cancer	2.24e-05	6.24e-05	CcSEcCtD
Maraviroc—Insomnia—Prednisone—hematologic cancer	2.24e-05	6.24e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—GMPS—hematologic cancer	2.23e-05	0.000137	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PHYH—hematologic cancer	2.23e-05	0.000137	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FTCD—hematologic cancer	2.23e-05	0.000137	CbGpPWpGaD
Maraviroc—Alopecia—Doxorubicin—hematologic cancer	2.23e-05	6.21e-05	CcSEcCtD
Maraviroc—Paraesthesia—Prednisone—hematologic cancer	2.22e-05	6.19e-05	CcSEcCtD
Maraviroc—Pruritus—Triamcinolone—hematologic cancer	2.22e-05	6.17e-05	CcSEcCtD
Maraviroc—Cough—Methotrexate—hematologic cancer	2.21e-05	6.16e-05	CcSEcCtD
Maraviroc—Mental disorder—Doxorubicin—hematologic cancer	2.21e-05	6.15e-05	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—hematologic cancer	2.2e-05	6.12e-05	CcSEcCtD
Maraviroc—Vomiting—Etoposide—hematologic cancer	2.2e-05	6.12e-05	CcSEcCtD
Maraviroc—Erythema—Doxorubicin—hematologic cancer	2.2e-05	6.11e-05	CcSEcCtD
Maraviroc—Malnutrition—Doxorubicin—hematologic cancer	2.2e-05	6.11e-05	CcSEcCtD
Maraviroc—Anaemia—Epirubicin—hematologic cancer	2.19e-05	6.11e-05	CcSEcCtD
Maraviroc—Rash—Etoposide—hematologic cancer	2.18e-05	6.07e-05	CcSEcCtD
Maraviroc—Dermatitis—Etoposide—hematologic cancer	2.18e-05	6.06e-05	CcSEcCtD
Maraviroc—Headache—Etoposide—hematologic cancer	2.16e-05	6.03e-05	CcSEcCtD
Maraviroc—Flatulence—Doxorubicin—hematologic cancer	2.16e-05	6.03e-05	CcSEcCtD
Maraviroc—Myalgia—Methotrexate—hematologic cancer	2.16e-05	6.01e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MAPK3—hematologic cancer	2.16e-05	0.000133	CbGpPWpGaD
Maraviroc—Decreased appetite—Prednisone—hematologic cancer	2.15e-05	5.99e-05	CcSEcCtD
Maraviroc—Rash—Prednisolone—hematologic cancer	2.15e-05	5.98e-05	CcSEcCtD
Maraviroc—Dermatitis—Prednisolone—hematologic cancer	2.15e-05	5.98e-05	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.14e-05	5.97e-05	CcSEcCtD
Maraviroc—Fatigue—Prednisone—hematologic cancer	2.13e-05	5.95e-05	CcSEcCtD
Maraviroc—Headache—Prednisolone—hematologic cancer	2.13e-05	5.94e-05	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—hematologic cancer	2.13e-05	5.94e-05	CcSEcCtD
Maraviroc—Syncope—Epirubicin—hematologic cancer	2.13e-05	5.93e-05	CcSEcCtD
Maraviroc—Leukopenia—Epirubicin—hematologic cancer	2.12e-05	5.92e-05	CcSEcCtD
Maraviroc—Constipation—Prednisone—hematologic cancer	2.12e-05	5.9e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MYC—hematologic cancer	2.1e-05	0.000129	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TGFB1—hematologic cancer	2.09e-05	0.000129	CbGpPWpGaD
Maraviroc—Loss of consciousness—Epirubicin—hematologic cancer	2.09e-05	5.81e-05	CcSEcCtD
Maraviroc—CCR5—Disease—AKT1—hematologic cancer	2.08e-05	0.000128	CbGpPWpGaD
Maraviroc—Dizziness—Triamcinolone—hematologic cancer	2.07e-05	5.77e-05	CcSEcCtD
Maraviroc—Cough—Epirubicin—hematologic cancer	2.07e-05	5.77e-05	CcSEcCtD
Maraviroc—Convulsion—Epirubicin—hematologic cancer	2.06e-05	5.73e-05	CcSEcCtD
Maraviroc—Infection—Methotrexate—hematologic cancer	2.06e-05	5.73e-05	CcSEcCtD
Maraviroc—Nausea—Etoposide—hematologic cancer	2.05e-05	5.71e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—SMPD3—hematologic cancer	2.04e-05	0.000126	CbGpPWpGaD
Maraviroc—Asthenia—Betamethasone—hematologic cancer	2.04e-05	5.68e-05	CcSEcCtD
Maraviroc—Asthenia—Dexamethasone—hematologic cancer	2.04e-05	5.68e-05	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—hematologic cancer	2.03e-05	5.65e-05	CcSEcCtD
Maraviroc—Anaemia—Doxorubicin—hematologic cancer	2.03e-05	5.65e-05	CcSEcCtD
Maraviroc—Gastrointestinal pain—Prednisone—hematologic cancer	2.02e-05	5.64e-05	CcSEcCtD
Maraviroc—Nausea—Prednisolone—hematologic cancer	2.02e-05	5.64e-05	CcSEcCtD
Maraviroc—Myalgia—Epirubicin—hematologic cancer	2.02e-05	5.63e-05	CcSEcCtD
Maraviroc—Anxiety—Epirubicin—hematologic cancer	2.01e-05	5.61e-05	CcSEcCtD
Maraviroc—Pruritus—Dexamethasone—hematologic cancer	2.01e-05	5.6e-05	CcSEcCtD
Maraviroc—Pruritus—Betamethasone—hematologic cancer	2.01e-05	5.6e-05	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—hematologic cancer	2.01e-05	5.6e-05	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.01e-05	5.59e-05	CcSEcCtD
Maraviroc—Discomfort—Epirubicin—hematologic cancer	2e-05	5.56e-05	CcSEcCtD
Maraviroc—Vomiting—Triamcinolone—hematologic cancer	1.99e-05	5.55e-05	CcSEcCtD
Maraviroc—Rash—Triamcinolone—hematologic cancer	1.98e-05	5.5e-05	CcSEcCtD
Maraviroc—Dermatitis—Triamcinolone—hematologic cancer	1.97e-05	5.5e-05	CcSEcCtD
Maraviroc—Anorexia—Methotrexate—hematologic cancer	1.97e-05	5.49e-05	CcSEcCtD
Maraviroc—Syncope—Doxorubicin—hematologic cancer	1.97e-05	5.48e-05	CcSEcCtD
Maraviroc—Leukopenia—Doxorubicin—hematologic cancer	1.96e-05	5.47e-05	CcSEcCtD
Maraviroc—Headache—Triamcinolone—hematologic cancer	1.96e-05	5.47e-05	CcSEcCtD
Maraviroc—Body temperature increased—Prednisone—hematologic cancer	1.96e-05	5.45e-05	CcSEcCtD
Maraviroc—Abdominal pain—Prednisone—hematologic cancer	1.96e-05	5.45e-05	CcSEcCtD
Maraviroc—Diarrhoea—Betamethasone—hematologic cancer	1.95e-05	5.42e-05	CcSEcCtD
Maraviroc—Diarrhoea—Dexamethasone—hematologic cancer	1.95e-05	5.42e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—KRAS—hematologic cancer	1.94e-05	0.000119	CbGpPWpGaD
Maraviroc—Oedema—Epirubicin—hematologic cancer	1.94e-05	5.39e-05	CcSEcCtD
Maraviroc—Loss of consciousness—Doxorubicin—hematologic cancer	1.93e-05	5.37e-05	CcSEcCtD
Maraviroc—Infection—Epirubicin—hematologic cancer	1.92e-05	5.36e-05	CcSEcCtD
Maraviroc—Cough—Doxorubicin—hematologic cancer	1.92e-05	5.34e-05	CcSEcCtD
Maraviroc—Shock—Epirubicin—hematologic cancer	1.9e-05	5.31e-05	CcSEcCtD
Maraviroc—Convulsion—Doxorubicin—hematologic cancer	1.9e-05	5.3e-05	CcSEcCtD
Maraviroc—Nervous system disorder—Epirubicin—hematologic cancer	1.9e-05	5.29e-05	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.88e-05	5.25e-05	CcSEcCtD
Maraviroc—Skin disorder—Epirubicin—hematologic cancer	1.88e-05	5.24e-05	CcSEcCtD
Maraviroc—Dizziness—Betamethasone—hematologic cancer	1.88e-05	5.24e-05	CcSEcCtD
Maraviroc—Dizziness—Dexamethasone—hematologic cancer	1.88e-05	5.24e-05	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—hematologic cancer	1.87e-05	5.21e-05	CcSEcCtD
Maraviroc—Myalgia—Doxorubicin—hematologic cancer	1.87e-05	5.21e-05	CcSEcCtD
Maraviroc—Anxiety—Doxorubicin—hematologic cancer	1.86e-05	5.19e-05	CcSEcCtD
Maraviroc—Nausea—Triamcinolone—hematologic cancer	1.86e-05	5.18e-05	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—hematologic cancer	1.86e-05	5.17e-05	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.86e-05	5.17e-05	CcSEcCtD
Maraviroc—Discomfort—Doxorubicin—hematologic cancer	1.85e-05	5.14e-05	CcSEcCtD
Maraviroc—Anorexia—Epirubicin—hematologic cancer	1.85e-05	5.14e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Prednisone—hematologic cancer	1.82e-05	5.08e-05	CcSEcCtD
Maraviroc—Vomiting—Dexamethasone—hematologic cancer	1.81e-05	5.03e-05	CcSEcCtD
Maraviroc—Vomiting—Betamethasone—hematologic cancer	1.81e-05	5.03e-05	CcSEcCtD
Maraviroc—Decreased appetite—Methotrexate—hematologic cancer	1.8e-05	5.01e-05	CcSEcCtD
Maraviroc—Rash—Dexamethasone—hematologic cancer	1.79e-05	4.99e-05	CcSEcCtD
Maraviroc—Rash—Betamethasone—hematologic cancer	1.79e-05	4.99e-05	CcSEcCtD
Maraviroc—Oedema—Doxorubicin—hematologic cancer	1.79e-05	4.99e-05	CcSEcCtD
Maraviroc—Dermatitis—Betamethasone—hematologic cancer	1.79e-05	4.99e-05	CcSEcCtD
Maraviroc—Dermatitis—Dexamethasone—hematologic cancer	1.79e-05	4.99e-05	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.79e-05	4.98e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.78e-05	0.00011	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—DCK—hematologic cancer	1.78e-05	0.00011	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ASNS—hematologic cancer	1.78e-05	0.00011	CbGpPWpGaD
Maraviroc—Fatigue—Methotrexate—hematologic cancer	1.78e-05	4.97e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—hematologic cancer	1.78e-05	0.00011	CbGpPWpGaD
Maraviroc—Headache—Dexamethasone—hematologic cancer	1.78e-05	4.96e-05	CcSEcCtD
Maraviroc—Headache—Betamethasone—hematologic cancer	1.78e-05	4.96e-05	CcSEcCtD
Maraviroc—Infection—Doxorubicin—hematologic cancer	1.78e-05	4.96e-05	CcSEcCtD
Maraviroc—Asthenia—Prednisone—hematologic cancer	1.78e-05	4.95e-05	CcSEcCtD
Maraviroc—Pain—Methotrexate—hematologic cancer	1.77e-05	4.93e-05	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.76e-05	4.91e-05	CcSEcCtD
Maraviroc—Shock—Doxorubicin—hematologic cancer	1.76e-05	4.91e-05	CcSEcCtD
Maraviroc—Nervous system disorder—Doxorubicin—hematologic cancer	1.76e-05	4.89e-05	CcSEcCtD
Maraviroc—Pruritus—Prednisone—hematologic cancer	1.75e-05	4.88e-05	CcSEcCtD
Maraviroc—Insomnia—Epirubicin—hematologic cancer	1.75e-05	4.88e-05	CcSEcCtD
Maraviroc—Skin disorder—Doxorubicin—hematologic cancer	1.74e-05	4.85e-05	CcSEcCtD
Maraviroc—Paraesthesia—Epirubicin—hematologic cancer	1.74e-05	4.84e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—TP53—hematologic cancer	1.72e-05	0.000106	CbGpPWpGaD
Maraviroc—Anorexia—Doxorubicin—hematologic cancer	1.71e-05	4.76e-05	CcSEcCtD
Maraviroc—Diarrhoea—Prednisone—hematologic cancer	1.69e-05	4.72e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—HDC—hematologic cancer	1.69e-05	0.000104	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Methotrexate—hematologic cancer	1.69e-05	4.71e-05	CcSEcCtD
Maraviroc—Nausea—Dexamethasone—hematologic cancer	1.69e-05	4.7e-05	CcSEcCtD
Maraviroc—Nausea—Betamethasone—hematologic cancer	1.69e-05	4.7e-05	CcSEcCtD
Maraviroc—Decreased appetite—Epirubicin—hematologic cancer	1.68e-05	4.69e-05	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.67e-05	4.66e-05	CcSEcCtD
Maraviroc—Fatigue—Epirubicin—hematologic cancer	1.67e-05	4.65e-05	CcSEcCtD
Maraviroc—Pain—Epirubicin—hematologic cancer	1.66e-05	4.61e-05	CcSEcCtD
Maraviroc—Constipation—Epirubicin—hematologic cancer	1.66e-05	4.61e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HRAS—hematologic cancer	1.65e-05	0.000101	CbGpPWpGaD
Maraviroc—Dizziness—Prednisone—hematologic cancer	1.64e-05	4.56e-05	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—hematologic cancer	1.64e-05	4.56e-05	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—hematologic cancer	1.64e-05	4.56e-05	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.63e-05	4.55e-05	CcSEcCtD
Maraviroc—Insomnia—Doxorubicin—hematologic cancer	1.62e-05	4.51e-05	CcSEcCtD
Maraviroc—Paraesthesia—Doxorubicin—hematologic cancer	1.61e-05	4.48e-05	CcSEcCtD
Maraviroc—Gastrointestinal pain—Epirubicin—hematologic cancer	1.58e-05	4.41e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—IL6—hematologic cancer	1.58e-05	9.71e-05	CbGpPWpGaD
Maraviroc—Vomiting—Prednisone—hematologic cancer	1.57e-05	4.38e-05	CcSEcCtD
Maraviroc—Rash—Prednisone—hematologic cancer	1.56e-05	4.35e-05	CcSEcCtD
Maraviroc—Dermatitis—Prednisone—hematologic cancer	1.56e-05	4.34e-05	CcSEcCtD
Maraviroc—Decreased appetite—Doxorubicin—hematologic cancer	1.56e-05	4.34e-05	CcSEcCtD
Maraviroc—Headache—Prednisone—hematologic cancer	1.55e-05	4.32e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—CDA—hematologic cancer	1.55e-05	9.52e-05	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.55e-05	4.31e-05	CcSEcCtD
Maraviroc—Fatigue—Doxorubicin—hematologic cancer	1.54e-05	4.3e-05	CcSEcCtD
Maraviroc—Constipation—Doxorubicin—hematologic cancer	1.53e-05	4.27e-05	CcSEcCtD
Maraviroc—Pain—Doxorubicin—hematologic cancer	1.53e-05	4.27e-05	CcSEcCtD
Maraviroc—Body temperature increased—Epirubicin—hematologic cancer	1.53e-05	4.26e-05	CcSEcCtD
Maraviroc—Abdominal pain—Epirubicin—hematologic cancer	1.53e-05	4.26e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Methotrexate—hematologic cancer	1.52e-05	4.25e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—PC—hematologic cancer	1.49e-05	9.17e-05	CbGpPWpGaD
Maraviroc—Asthenia—Methotrexate—hematologic cancer	1.48e-05	4.13e-05	CcSEcCtD
Maraviroc—Nausea—Prednisone—hematologic cancer	1.47e-05	4.1e-05	CcSEcCtD
Maraviroc—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.46e-05	4.08e-05	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—hematologic cancer	1.46e-05	4.08e-05	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—AKT1—hematologic cancer	1.46e-05	8.96e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.44e-05	8.85e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GBA—hematologic cancer	1.44e-05	8.85e-05	CbGpPWpGaD
Maraviroc—Hypersensitivity—Epirubicin—hematologic cancer	1.43e-05	3.97e-05	CcSEcCtD
Maraviroc—Body temperature increased—Doxorubicin—hematologic cancer	1.42e-05	3.94e-05	CcSEcCtD
Maraviroc—Abdominal pain—Doxorubicin—hematologic cancer	1.42e-05	3.94e-05	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—hematologic cancer	1.42e-05	3.94e-05	CcSEcCtD
Maraviroc—Asthenia—Epirubicin—hematologic cancer	1.39e-05	3.87e-05	CcSEcCtD
Maraviroc—Pruritus—Epirubicin—hematologic cancer	1.37e-05	3.82e-05	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—hematologic cancer	1.37e-05	3.81e-05	CcSEcCtD
Maraviroc—Diarrhoea—Epirubicin—hematologic cancer	1.32e-05	3.69e-05	CcSEcCtD
Maraviroc—Hypersensitivity—Doxorubicin—hematologic cancer	1.32e-05	3.68e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—MTAP—hematologic cancer	1.32e-05	8.1e-05	CbGpPWpGaD
Maraviroc—Vomiting—Methotrexate—hematologic cancer	1.32e-05	3.66e-05	CcSEcCtD
Maraviroc—Rash—Methotrexate—hematologic cancer	1.3e-05	3.63e-05	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—hematologic cancer	1.3e-05	3.63e-05	CcSEcCtD
Maraviroc—Headache—Methotrexate—hematologic cancer	1.3e-05	3.61e-05	CcSEcCtD
Maraviroc—Asthenia—Doxorubicin—hematologic cancer	1.29e-05	3.58e-05	CcSEcCtD
Maraviroc—Dizziness—Epirubicin—hematologic cancer	1.28e-05	3.57e-05	CcSEcCtD
Maraviroc—Pruritus—Doxorubicin—hematologic cancer	1.27e-05	3.53e-05	CcSEcCtD
Maraviroc—Vomiting—Epirubicin—hematologic cancer	1.23e-05	3.43e-05	CcSEcCtD
Maraviroc—Nausea—Methotrexate—hematologic cancer	1.23e-05	3.42e-05	CcSEcCtD
Maraviroc—Diarrhoea—Doxorubicin—hematologic cancer	1.23e-05	3.41e-05	CcSEcCtD
Maraviroc—Rash—Epirubicin—hematologic cancer	1.22e-05	3.4e-05	CcSEcCtD
Maraviroc—Dermatitis—Epirubicin—hematologic cancer	1.22e-05	3.4e-05	CcSEcCtD
Maraviroc—Headache—Epirubicin—hematologic cancer	1.21e-05	3.38e-05	CcSEcCtD
Maraviroc—Dizziness—Doxorubicin—hematologic cancer	1.18e-05	3.3e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—FHL2—hematologic cancer	1.17e-05	7.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AGRN—hematologic cancer	1.15e-05	7.08e-05	CbGpPWpGaD
Maraviroc—Nausea—Epirubicin—hematologic cancer	1.15e-05	3.2e-05	CcSEcCtD
Maraviroc—Vomiting—Doxorubicin—hematologic cancer	1.14e-05	3.17e-05	CcSEcCtD
Maraviroc—Rash—Doxorubicin—hematologic cancer	1.13e-05	3.15e-05	CcSEcCtD
Maraviroc—Dermatitis—Doxorubicin—hematologic cancer	1.13e-05	3.14e-05	CcSEcCtD
Maraviroc—Headache—Doxorubicin—hematologic cancer	1.12e-05	3.13e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—IDH2—hematologic cancer	1.09e-05	6.71e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HMMR—hematologic cancer	1.09e-05	6.71e-05	CbGpPWpGaD
Maraviroc—Nausea—Doxorubicin—hematologic cancer	1.06e-05	2.96e-05	CcSEcCtD
Maraviroc—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.03e-05	6.31e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CA9—hematologic cancer	9.97e-06	6.14e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACP5—hematologic cancer	9.97e-06	6.14e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOR2—hematologic cancer	9.84e-06	6.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—IDH1—hematologic cancer	9.38e-06	5.77e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—TXN—hematologic cancer	9.27e-06	5.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCC3—hematologic cancer	9.27e-06	5.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTO1—hematologic cancer	9.27e-06	5.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SPHK1—hematologic cancer	9.07e-06	5.58e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGT1A1—hematologic cancer	8.72e-06	5.36e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CRABP1—hematologic cancer	8.48e-06	5.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC22A1—hematologic cancer	8.48e-06	5.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALOX5—hematologic cancer	8.26e-06	5.08e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NUP98—hematologic cancer	8e-06	4.92e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ADCY7—hematologic cancer	7.77e-06	4.78e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOA3—hematologic cancer	7.77e-06	4.78e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NUP214—hematologic cancer	7.71e-06	4.75e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCG2—hematologic cancer	7.56e-06	4.65e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTR—hematologic cancer	7.56e-06	4.65e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ENO2—hematologic cancer	7.41e-06	4.56e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTT1—hematologic cancer	7.19e-06	4.42e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SDC1—hematologic cancer	7.03e-06	4.32e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NQO1—hematologic cancer	5.97e-06	3.68e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CD44—hematologic cancer	5.97e-06	3.68e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYCS—hematologic cancer	5.65e-06	3.48e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	5.62e-06	3.46e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTP1—hematologic cancer	4.98e-06	3.07e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCB1—hematologic cancer	4.72e-06	2.9e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GSTM1—hematologic cancer	4.58e-06	2.82e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—NCOR1—hematologic cancer	4.58e-06	2.82e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.05e-06	2.49e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.4e-06	2.09e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.15e-06	1.94e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.99e-06	1.84e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—hematologic cancer	2.95e-06	1.82e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3R1—hematologic cancer	2.82e-06	1.74e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.61e-06	1.6e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—hematologic cancer	2.25e-06	1.39e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—EP300—hematologic cancer	2.15e-06	1.32e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.59e-06	9.77e-06	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—hematologic cancer	1.3e-06	7.98e-06	CbGpPWpGaD
